CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Other Restructuring Costs
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Other Restructuring Costs of $20.80 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherRestructuringCosts · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for the quarter ending 2026-06-27 was $20.80M, a 26.93% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for the quarter ending 2026-03-28 was $25.36M, a 64.36% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for the quarter ending 2025-12-27 was $14.41M, a 49.73% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for the quarter ending 2025-09-27 was $12.49M, a 203.82% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for fiscal 2025 was $70.80M, a 34.10% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for fiscal 2024 was $52.80M, a 192.13% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for fiscal 2023 was $18.07M, a 319.16% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. other restructuring costs for fiscal 2022 was $4.31M.
| Period end | Other Restructuring Costs 3 month | Other Restructuring Costs 6 month | Other Restructuring Costs 9 month | Other Restructuring Costs 12 month |
|---|---|---|---|---|
| 2026-06-27 | $20.80M 10-Q · filed 2026-08-05 | $46.17M 10-Q · filed 2026-08-05 | $60.58M derived: sum of 3 quarters · filed 2026-08-05 | $73.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $25.36M 10-Q · filed 2026-05-07 | $39.77M derived: sum of 2 quarters · filed 2026-05-07 | $52.26M derived: sum of 3 quarters · filed 2026-05-07 | $80.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $26.90M derived: sum of 2 quarters · filed 2026-02-18 | $55.37M derived: sum of 3 quarters · filed 2026-08-05 | $70.80M 10-K · filed 2026-02-18 |
| 2025-09-27 | $12.49M 10-Q · filed 2025-11-05 | $40.96M derived: sum of 2 quarters · filed 2026-08-05 | $56.39M 10-Q · filed 2025-11-05 | $85.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $28.47M 10-Q · filed 2026-08-05 | $43.90M 10-Q · filed 2026-08-05 | $72.57M derived: sum of 3 quarters · filed 2026-08-05 | $76.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $15.43M 10-Q · filed 2026-05-07 | $44.10M derived: sum of 2 quarters · filed 2026-05-07 | $48.21M derived: sum of 3 quarters · filed 2026-05-07 | $60.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $28.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $32.78M derived: sum of 2 quarters · filed 2026-02-18 | $44.84M derived: sum of 3 quarters · filed 2026-02-18 | $52.80M 10-K · filed 2026-02-18 |
| 2024-09-28 | $4.11M 10-Q · filed 2025-11-05 | $16.17M derived: sum of 2 quarters · filed 2025-11-05 | $24.13M 10-Q · filed 2025-11-05 | $27.87M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $12.06M 10-Q · filed 2025-08-06 | $20.02M 10-Q · filed 2025-08-06 | $23.76M derived: sum of 3 quarters · filed 2026-02-18 | $35.34M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $7.96M 10-Q · filed 2025-05-07 | $11.70M derived: sum of 2 quarters · filed 2026-02-18 | $23.28M derived: sum of 3 quarters · filed 2026-02-18 | $23.46M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $15.32M derived: sum of 2 quarters · filed 2026-02-18 | $15.50M derived: sum of 3 quarters · filed 2026-02-18 | $18.07M 10-K · filed 2026-02-18 |
| 2023-09-30 | $11.58M 10-Q · filed 2024-11-06 | $11.77M derived: sum of 2 quarters · filed 2024-11-06 | $14.34M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $182.00K 10-Q · filed 2024-08-07 | $2.75M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $4.31M 10-K · filed 2025-02-19 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $100.00K derived: sum of 2 quarters · filed 2017-11-09 | $400.00K 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $100.00K 10-Q · filed 2017-08-09 | $400.00K 10-Q · filed 2017-08-09 | ||
| 2016-09-24 | $800.00K 10-Q · filed 2017-11-09 | $800.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |